Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.7K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.7K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

763
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
763
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.5K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.5K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

368
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
368
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

454
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
454
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

400
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
400

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis, treatment and monitoring of pediatric Behçet's disease: Systematic literature review informing the ISSAID/PRES recommendations.

Autoimmunity reviews·2026
Same author

Haemophilia Management in Natural Disasters-From Field to Consensus Report.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Crimean-Congo Hemorrhagic Fever in Children: Secondary Hemophagocytic Lymphohistiocytosis and Time-course of Biomarkers in a Single-Center Cohort (2019-25).

Journal of tropical pediatrics·2026
Same author

Tumor necrosis factor inhibitor-related autoimmune disorders in pediatric rheumatology practice: a multicenter nationwide study.

Pediatric rheumatology online journal·2026
Same author

Factors predicting the severity of gastrointestinal involvement in children with IgA vasculitis? A Turkish multicenter cohort study.

European journal of pediatrics·2026
Same author

The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries - For Whom, by Whom and Where?

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026

Related Experiment Video

Updated: Dec 21, 2025

Differentiating Functional Roles of Gene Expression from Immune and Non-immune Cells in Mouse Colitis by Bone Marrow Transplantation
14:43

Differentiating Functional Roles of Gene Expression from Immune and Non-immune Cells in Mouse Colitis by Bone Marrow Transplantation

Published on: October 1, 2012

18.7K

Colchicine and Leukopenia: Clinical Implications.

Erdal Sag1, Yagmur Bayindir1, Aydin Adiguzel1

  • 1Division of Pediatric Rheumatology, Department of Pediatrics, Ankara, Turkey.

The Journal of Pediatrics
|May 18, 2020
PubMed
Summary

Colchicine is a primary treatment for familial Mediterranean fever. This study found that leukopenia occurred in 10.8% of patients but was reversible and did not increase infection rates.

Keywords:
FMFcolchicineleukopenia

More Related Videos

Rapid Magnetic-microbead Method for Efficient Purification of Low-density Neutrophils
08:14

Rapid Magnetic-microbead Method for Efficient Purification of Low-density Neutrophils

Published on: November 11, 2025

192
The Isolation and Characterization of Low- and Normal- Density Neutrophils from Whole Blood
07:17

The Isolation and Characterization of Low- and Normal- Density Neutrophils from Whole Blood

Published on: February 7, 2025

1.2K

Related Experiment Videos

Last Updated: Dec 21, 2025

Differentiating Functional Roles of Gene Expression from Immune and Non-immune Cells in Mouse Colitis by Bone Marrow Transplantation
14:43

Differentiating Functional Roles of Gene Expression from Immune and Non-immune Cells in Mouse Colitis by Bone Marrow Transplantation

Published on: October 1, 2012

18.7K
Rapid Magnetic-microbead Method for Efficient Purification of Low-density Neutrophils
08:14

Rapid Magnetic-microbead Method for Efficient Purification of Low-density Neutrophils

Published on: November 11, 2025

192
The Isolation and Characterization of Low- and Normal- Density Neutrophils from Whole Blood
07:17

The Isolation and Characterization of Low- and Normal- Density Neutrophils from Whole Blood

Published on: February 7, 2025

1.2K

Area of Science:

  • Rheumatology
  • Genetics
  • Pharmacology

Background:

  • Familial Mediterranean fever (FMF) is a genetic autoinflammatory disorder.
  • Colchicine is the established first-line therapy for managing FMF.
  • Understanding the safety profile of colchicine, particularly hematological side effects, is crucial for long-term patient management.

Observation:

  • This study evaluated 213 patients diagnosed with familial Mediterranean fever.
  • Patients were treated with standard daily doses of colchicine, ranging from 0.5 to 2.0 mg.
  • The occurrence and severity of leukopenia were specifically monitored.

Findings:

  • A total of 23 patients (10.8%) experienced reversible leukopenia during colchicine treatment.
  • Of these, 3 patients had moderate leukopenia, and no patients presented with severe leukopenia.
  • The incidence of infections was not significantly increased in patients who developed leukopenia.

Implications:

  • Reversible leukopenia is a potential, generally mild side effect of standard-dose colchicine therapy in familial Mediterranean fever.
  • The absence of increased infection rates suggests that colchicine can be safely continued in most FMF patients even with mild to moderate leukopenia.
  • These findings support the continued use of colchicine as the mainstay treatment for FMF, with careful monitoring for hematological parameters.